Bioactive Materials最新文献

{"title":"Light-cured millineedle platform delivers “nano-pomegranate” for combinatorial electrodynamic therapy and cuproptosis against oral carcinoma","authors":"Guoyun Wan ,&nbsp;Jiayu Chen ,&nbsp;Yingying Zhou ,&nbsp;Lina Dou ,&nbsp;Dongmei Wang ,&nbsp;Nannan Wang ,&nbsp;Hongli Chen ,&nbsp;Haijiao Wang ,&nbsp;Xianwen Wang ,&nbsp;Zhijun Yang ,&nbsp;Dan Ding","doi":"10.1016/j.bioactmat.2025.07.032","DOIUrl":"10.1016/j.bioactmat.2025.07.032","url":null,"abstract":"<div><div>Monomodal therapies often fail to eradicate tumors due to the complexity of tumorigenesis and microenvironmental resistance. Electrodynamic therapy (EDT) and cuproptosis as emerging antitumor therapies have attracted widespread attention and become the promising strategies for tumor treatment due to their unique advantages. Here, we first time present a light-cured millineedle as a tool for co-delivering a nano-pomegranate (N-PG) platform and Cu²⁺ by integrating EDT and cuproptosis induction for combined oral cancer treatment. This platform N-PG/NSC consists of Pt-doped dendritic mesoporous large silica nanoparticles (Pt@DLMSN) loaded copper ionophore NSC319726, enabling dual therapeutic actions: (1) N-PG/NSC-based EDT-driven generation of hydroxyl radicals (•OH) via H₂O decomposition under electric fields, circumventing hypoxia-related resistance, and (2) NSC imported Cu²⁺-mediated cuproptosis through mitochondrial dysfunction induced by DLAT oligomerization and Fe-S cluster protein depletion. The millineedle ensures precise and weak-leakage intratumoral delivery, while simultaneously triggering immunogenic cell death (ICD) to prime antitumor immunity. When combined with the TLR7/8 agonist R848, the platform elicits systemic immune activation, effectively suppressing both primary and abscopal oral tumors. As the first reported integration of MN-assisted drug delivery, hypoxia-tolerant EDT, and cuproptosis, this work establishes a translatable paradigm for multimodal cancer therapy, merging localized cytotoxicity with immune reprogramming for enhanced clinical outcomes.</div></div>","PeriodicalId":8762,"journal":{"name":"Bioactive Materials","volume":"53 ","pages":"Pages 718-736"},"PeriodicalIF":18.0,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144756983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of ARH2 by pH/ROS-responsive nanosystem for improved lung adenocarcinoma immunochemotherapy","authors":"Rui Cai ,&nbsp;Meng Wang ,&nbsp;Mengting Pan ,&nbsp;Zhiwu Zhang ,&nbsp;Qiang Jia ,&nbsp;Longbao Feng ,&nbsp;Zhongjian Yu ,&nbsp;Lu Liu ,&nbsp;Tongyu Zhu ,&nbsp;Silin Cai ,&nbsp;Han Tian ,&nbsp;Jiangyu Zhang ,&nbsp;Rui Guo ,&nbsp;Yanfang Zheng","doi":"10.1016/j.bioactmat.2025.07.042","DOIUrl":"10.1016/j.bioactmat.2025.07.042","url":null,"abstract":"<div><div>Immunotherapy resistance remains a substantial barrier to improving treatment outcomes for patients with lung adenocarcinoma (LUAD). Identifying effective immunotherapy target is crucial for enhancing therapeutic efficacy in LUAD. Through database analysis, we discovered that ADP ribosylhydrolase-like 1 (ADPRHL1, ARH2) is associated with immunosuppression. In this study, we first demonstrated that the increased presence of ARH2-positive macrophages in LUAD tumors is associated with immunosuppression. Furthermore, ARH2 promotes M2 macrophage polarization and suppresses immune responses by regulating the FPR2/PI3K/AKT signaling pathway. Additionally, we found that artesunate (ART) can induce necroptosis in LUAD cells and activate antitumor immune responses. To translate these findings into a clinically viable therapeutic approach, we developed a pH/ROS-responsive nanosystem capable of co-delivering siARH2 and ART. This nanosystem effectively activated immune responses in both tumor cells and tumor-associated macrophages. Furthermore, the nanosystem demonstrated excellent <em>in vivo</em> safety, precise PD-L1 targeting, and responsiveness to ROS and pH variations. It considerably suppressed the malignant phenotype of tumor cells induced by macrophages and enhanced T-cell-mediated immune responses. Overall, targeting ARH2 in combination with ART represents a promising novel strategy for the treatment of LUAD.</div></div>","PeriodicalId":8762,"journal":{"name":"Bioactive Materials","volume":"53 ","pages":"Pages 737-753"},"PeriodicalIF":18.0,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144756989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Preclinical evaluation of the safety and effectiveness of a new bioartificial cornea” [Bioact. Mater. 2023 (8) 29 265–278]","authors":"Yansha Hao ,&nbsp;Jingting Zhou ,&nbsp;Ju Tan ,&nbsp;Feng Xiang ,&nbsp;Zhongliang Qin ,&nbsp;Jun Yao ,&nbsp;Gang Li ,&nbsp;Mingcan Yang ,&nbsp;Lingqin Zeng ,&nbsp;Wen Zeng ,&nbsp;Chuhong Zhu","doi":"10.1016/j.bioactmat.2025.07.011","DOIUrl":"10.1016/j.bioactmat.2025.07.011","url":null,"abstract":"<div><div>Cross-linking agents are frequently used to restore corneal properties after decellularization, and it is especially important to select an appropriate method to avoid excessive cross-linking. In addition, how to promote wound healing and how to improve scar formation require further investigation. To ensure the safety and efficacy of animal-derived products, we designed bioartificial corneas (BACs) according to the criteria for Class III medical devices. Our BACs do not require cross-linking agents and increase mechanical strength via self-cross-linking of aldehyde-modified hyaluronic acid (AHA) and carboxymethyl chitosan (CMC) on the surface of decellularized porcine corneas (DPCs). The results showed that the BACs had good biocompatibility and transparency, and the modification enhanced their antibacterial and anti-inflammatory properties in vitro. Preclinical animal studies showed that the BACs can rapidly regenerate the epithelium and restore vision within a month. After 3 months, the BACs were gradually filled with epithelial, stromal, and neuronal cells, and after 6 months, their transparency and histology were almost normal. In addition, side effects such as corneal neovascularization, conjunctival hyperemia, and ciliary body hyperemia rarely occur in vivo. Therefore, these BACs show promise for clinical application for the treatment of infectious corneal ulcers and as a temporary covering for corneal perforations to achieve the more time.</div></div>","PeriodicalId":8762,"journal":{"name":"Bioactive Materials","volume":"53 ","pages":"Pages 704-705"},"PeriodicalIF":18.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biocompatible liquid-infused titanium minimizes oral biofilm adhesion in flow chamber and 3D implant-tissue-biofilm in vitro models","authors":"Katharina Doll-Nikutta ,&nbsp;Carina Mikolai ,&nbsp;Nils Heine ,&nbsp;Kestutis Kurselis ,&nbsp;Elena Fadeeva ,&nbsp;Nicolas Debener ,&nbsp;Beate Legutko ,&nbsp;Charlotte Kreuzkamp ,&nbsp;Vannila Prasanthan ,&nbsp;Janina Bahnemann ,&nbsp;Boris N. Chichkov ,&nbsp;Meike Stiesch","doi":"10.1016/j.bioactmat.2025.07.048","DOIUrl":"10.1016/j.bioactmat.2025.07.048","url":null,"abstract":"<div><div>Biomedical implants are susceptible to bacterial colonization, which can lead to challenging implant-associated infections. In particular, dental implant abutments – which are continuously exposed to bacteria within the oral cavity – stand to greatly benefit from strategies which inhibit the development of bacterial biofilms. Liquid-infused titanium surfaces have demonstrated excellent biofilm repellency, but to date have not been analyzed with substances suitable for medical device approval in terms of biocompatibility under conditions mimicking the environment of dental implant abutments. In this study, different medical-grade lubricants coated onto laser-structured titanium were screened for stability and water-repellency – with the results suggesting that unmodified structured titanium coated with silicone oil was the most promising combination of materials. When analyzing biofilm formation, the coated surfaces showed a statistically significant reduction in oral commensal <em>Streptococcus oralis</em> biofilms grown under static conditions as well as oral multispecies biofilms grown under salivation-resembling flow conditions. This biofilm-reducing effect was also observed when the coated surface interfaced with a 3D implant-tissue-oral-bacterial-biofilm (INTER_bACT) <em>in vitro</em> model, which allows for the direct interaction of human tissue and oral multispecies biofilm at the implant interface. Importantly, this biofilm reduction was not due to toxicity of the coated surfaces, but is most likely attributable to inhibition of bacterial attachment. Additionally, the surfaces were not cytotoxic, without altering adjacent soft tissue or causing elevated pro-inflammatory cytokine secretion. These findings highlight the promise of biocompatible liquid-infused titanium surfaces as biofilm-repellent implant abutment modifications and provide the basis for further investigations in targeted pre-clinical studies.</div></div>","PeriodicalId":8762,"journal":{"name":"Bioactive Materials","volume":"53 ","pages":"Pages 706-717"},"PeriodicalIF":18.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144756980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in biomaterials and bioactive solutions for lumbar spine fusion cages: Current trends and future perspectives","authors":"Iulian Antoniac ,&nbsp;Veronica Manescu (Paltanea) ,&nbsp;Gheorghe Paltanea ,&nbsp;Aurora Antoniac ,&nbsp;Marco Fosca ,&nbsp;Dan Laptoiu ,&nbsp;Julietta V. Rau","doi":"10.1016/j.bioactmat.2025.07.035","DOIUrl":"10.1016/j.bioactmat.2025.07.035","url":null,"abstract":"<div><div>Spinal fusion is considered today as the last treatment option for different spinal conditions, such as degenerative and infectious illnesses. It consists of fusing two or more vertebrae to obtain reinforcement/fixation based on several methods used to sustain osteosynthesis and grafting, such as cage insertion in the intervertebral space, which provides an important level of mechanical stability, impacting only a low amount of the natural biomechanics of the spine and facilitating the implant bony ingrowth. This review paper first explores the background of intervertebral fusion, emphasizing medical applications and material properties of interbody fusion cages. It then provides a brief historical overview and discusses antibacterial efficacy-related issues. Additionally, some of the most met-in-clinical practice lumbar interbody cages with a detailed description of their geometry and examples of clinical trials performed worldwide are provided. The biomaterials used in lumbar cage manufacture are comprehensively described. In the last part of this review paper, special attention is devoted to prospective biomaterials and coatings for spine fusion cages. Firstly, the rationale for using Mg-based alloys or high osteogenic polycaprolactone as biodegradable and bioresorbable alternatives in the spinal cage industry, addressing the clinical limitations of traditional Ti alloys and polyether ether ketone, is provided. Then, a more conservative approach, focusing on the use of bioactive or antibacterial coatings on the already certified biomaterials, is presented as a second alternative to the existing products on the market. Relevant literature studies are reviewed, and the osteointegrative, bioactive, or antibacterial character of the coatings is explained. Finally, our review identifies current clinical limitations and offers future perspectives that will provide better bioactive solutions, improving the existing biomaterials.</div></div>","PeriodicalId":8762,"journal":{"name":"Bioactive Materials","volume":"53 ","pages":"Pages 656-703"},"PeriodicalIF":18.0,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144739655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic modulation-driven self-reinforcing pyroptosis-STING nanoadjuvant for potentiated metalloimmunotherapy","authors":"Linzhu Zhang ,&nbsp;Di Wang ,&nbsp;Yiming Liu ,&nbsp;Nailin Yang ,&nbsp;Shumin Sun ,&nbsp;Chunjie Wang ,&nbsp;Duo Wang ,&nbsp;Jihu Nie ,&nbsp;Juan Qin ,&nbsp;Lei Zhang ,&nbsp;Liang Cheng ,&nbsp;Haidong Zhu","doi":"10.1016/j.bioactmat.2025.07.040","DOIUrl":"10.1016/j.bioactmat.2025.07.040","url":null,"abstract":"<div><div>Pyroptosis is a critical process that triggers inflammatory responses and mitochondrial DNA (mtDNA) release, thereby activating the cGAS-STING pathway. However, tumor metabolism, particularly glycolysis, often suppresses immune activation. To address this, we developed GOCoF₂, a self-amplifying pyroptosis-STING nanoadjuvant that integrates glucose oxidase (GOx) with cobalt fluoride (CoF₂) nanoenzymes. This nanoadjuvant excelled in converting intratumoral H₂O₂ into reactive oxygen species (ROS), inducing cell pyroptosis. Its self-sustaining mechanism involved glucose depletion and continuous H₂O₂ generation, ensuring persistent catalytic activity. This metabolic manipulation and induction of oxidative stress significantly enhance pyroptosis in tumor cells. The released mtDNA subsequently activated the cGAS-STING pathway, with Co²⁺ further amplifying this effect. Notably, glucose-dependent TREX2 inhibition intensified cGAS-STING activation through metabolic regulation, leading to a strong immune response and tumor growth suppression. When combined with immune checkpoint blockade therapy, GOCoF₂ significantly inhibited primary and distant tumor progression via systemic immune activation. Additionally, we formulated GOCoF₂-lipiodol for transarterial embolization, which demonstrated superior efficacy in a rat model of orthotopic hepatocellular carcinoma. This study not only sheds light on the intricate relationship between tumor metabolism and immune regulation but also introduces a novel therapeutic approach for hepatocellular carcinoma.</div></div>","PeriodicalId":8762,"journal":{"name":"Bioactive Materials","volume":"53 ","pages":"Pages 641-655"},"PeriodicalIF":18.0,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcutaneous electrotherapy of facial nerve injuries based on dissolvable conductive microneedles","authors":"Long Lin ,&nbsp;Xiaojing Yuan ,&nbsp;Lili Ma ,&nbsp;Liang Xu ,&nbsp;Wenyue Xie ,&nbsp;Ying Jiang ,&nbsp;Jidong Xiu ,&nbsp;Hongwei Xu ,&nbsp;Zhuoling Tian ,&nbsp;Jianan Qu ,&nbsp;Chunhui Zhao ,&nbsp;Zuoying Yuan ,&nbsp;Huilin Liu ,&nbsp;Jianyong Huang ,&nbsp;Xing Wang","doi":"10.1016/j.bioactmat.2025.07.013","DOIUrl":"10.1016/j.bioactmat.2025.07.013","url":null,"abstract":"<div><div>Local electrical stimulation (LES) is a widely used clinical method to treat peripheral nerve injury. However, existing plate electrodes (PE) usually suffer from low electronic transport efficiency, whereas acupuncture electrical stimulation may cause damage to normal tissues. There is an urgent need to develop an innovative LES technique with efficient electronic transport, minimal tissue injury and enhanced biosafety. Here, we present a new stretchable transcutaneous electrical stimulation system (STESS) that integrates dissolvable conductive microneedles (DCMN) for optimal skin penetration and electronic transport, along with snake-like electrodes that offer superior flexibility, which can effectively penetrate the stratum corneum, enabling deep tissue electrostimulation with minimal injury. <em>In vitro</em> studies and 3D finite-element analysis demonstrate that the DCMN-based electrotherapy significantly enhances subcutaneous nerve stimulation compared to the conventional PE-based technique. By diminishing the electrical resistance of the stratum corneum, the DCMN-based electrotherapy has shown remarkable <em>in vivo</em> therapeutic efficacy in a rat facial nerve crush injury model. This will pave the way for innovative physiotherapeutic methodologies in the realm of neurological rehabilitation.</div></div>","PeriodicalId":8762,"journal":{"name":"Bioactive Materials","volume":"53 ","pages":"Pages 630-640"},"PeriodicalIF":18.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery","authors":"Yu Chen ,&nbsp;Haifu Sun ,&nbsp;Yonggang Li ,&nbsp;Xixi Han ,&nbsp;Yuqing Yang ,&nbsp;Zheng Chen ,&nbsp;Xuequan Zhao ,&nbsp;Yuchen Qian ,&nbsp;Xishui Liu ,&nbsp;Feng Zhou ,&nbsp;Jiaxiang Bai ,&nbsp;Yusen Qiao","doi":"10.1016/j.bioactmat.2025.07.033","DOIUrl":"10.1016/j.bioactmat.2025.07.033","url":null,"abstract":"<div><div>As an innovative physiotherapeutic approach, magnetic hyperthermia therapy (MHT) has unique advantages including minimal invasiveness, precise temperature control, and deep tissue penetration capabilities. It offers unparalleled control over heating areas and temperatures, boasts high efficiency, and results in excellent tissue penetration, while remaining independent of biological tissues. With vast potential in biomedical applications ranging from antitumor therapy to thrombus dissolution, MHT harnesses magnetic nanoparticles (MNPs) to convert magnetic energy into thermal energy under an alternating magnetic field (AMF), thereby achieving therapeutic effects. Advanced magnetic nanocomposite platforms based on magnetic nanoparticles can avoid various risks associated with traditional tools, achieving precise, on-demand, or continuous targeted drug delivery and release through multiple approaches. The potential clinical applications of magnetic hyperthermia therapy are being progressively developed. The present article presents an exhaustive review of the research progress in magnetic hyperthermia therapy. Initially, the overall landscape of MHT was outlined, including physical heat generation mechanisms, types of magnetic nanoparticles and conductive nonmagnetic materials, strategies to increase the thermal efficiency of MNPs, and experimental evidence and research progress on “hot-spot” effects. This review has focused on biomedical applications and targeted drug delivery of innovative combination therapy strategies based on MHT. The progress of clinical trials on MNPs-mediated MHT (MNPs-MHT) is summarized below. Furthermore, the limitations, major challenges and prospects in the clinical translation of MHT are discussed. The objective of this work is to provide a panoramic view of biomedical applications and targeted drug delivery of MHT, which can potentially guide researchers and facilitate the successful implementation of advanced MNPs-MHT systems in the future.</div></div>","PeriodicalId":8762,"journal":{"name":"Bioactive Materials","volume":"53 ","pages":"Pages 591-629"},"PeriodicalIF":18.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144711544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supramolecular drug-laden hydrogel based on structural tautomerization enhances drug delivery for rheumatoid arthritis treatment","authors":"Hao Li ,&nbsp;Yuanning Lyu ,&nbsp;Ruinan Wang ,&nbsp;Hong Yu ,&nbsp;Mingxin Lin ,&nbsp;Zhuo Li ,&nbsp;Yanlin Zhong ,&nbsp;Puyi Sheng ,&nbsp;Kunyu Zhang ,&nbsp;Weiming Liao ,&nbsp;Liming Bian","doi":"10.1016/j.bioactmat.2025.07.039","DOIUrl":"10.1016/j.bioactmat.2025.07.039","url":null,"abstract":"<div><div>Rheumatoid arthritis (RA) is a major autoimmune disease characterized by significant joint inflammation and bone destruction. Many first-line RA treatment drugs such as methotrexate (MTX) have limited solubility in major solvents and are difficult to be delivered to RA joints in a sustained manner. Meanwhile, the efficient co-delivery of osteoinductive ions such as magnesium ions (Mg²⁺) for RA treatment is also challenging due to the uncontrolled burst release. By capitalizing on the enhanced supramolecular interactions of cyanuric acid (CYA) upon the pH-induced keto-enol tautomerization, a supramolecular hydrogel (Gel-MTX/Mg) with efficient co-delivery of MTX and Mg²⁺ is proposed. This hydrogel features pH-responsive on-demand release of MTX and Mg²⁺ in RA joints triggered by the pathological pH-induced keto-enol tautomerization of CYA. The release of MTX and Mg²⁺ from the Gel-MTX/Mg hydrogel induces anti-inflammatory M2 macrophage polarization, inhibits osteoclast differentiation, and enhances osteoblastic differentiation. Furthermore, RNA-seq results reveal that the Gel-MTX/Mg hydrogel promotes the enrichment of signaling pathways related to anti-inflammatory and bone-remodeling activities. One-time intra-articular administration of the Gel-MTX/Mg hydrogel significantly suppresses inflammation symptoms and protects bone and cartilage in a rat model. This supramolecular hydrogel that is capable of simultaneously delivering both therapeutic drugs and ions in response to pathological conditions has promising potential for the treatment of RA and other inflammatory and bone-degenerative diseases.</div></div>","PeriodicalId":8762,"journal":{"name":"Bioactive Materials","volume":"53 ","pages":"Pages 495-506"},"PeriodicalIF":18.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144711540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomolecule-functionalized dental implant surfaces: Towards augmenting soft tissue integration","authors":"Ghazal Shineh ,&nbsp;Leila Mamizadeh Janghour ,&nbsp;Yiyun Xia ,&nbsp;Jiayan Shao ,&nbsp;Karan Gulati ,&nbsp;Giselle C. Yeo ,&nbsp;Behnam Akhavan","doi":"10.1016/j.bioactmat.2025.07.005","DOIUrl":"10.1016/j.bioactmat.2025.07.005","url":null,"abstract":"<div><div>Dental implants are the primary solution for tooth replacement, providing both aesthetic and functional restoration. Their long-term success depends not only on osseointegration but also on robust peri-implant soft tissue integration (PSTI), particularly in the transmucosal region, where a stable epithelial seal is critical to preventing microbial infiltration and peri-implant inflammation. While surface topography modifications such as roughness, morphology, and porosity influence gingival cell behavior, passive surface modifications alone are often insufficient to promote rapid PSTI. This raises a fundamental question in dental implant design: How can implant surfaces be bioengineered to actively promote PSTI rather than passively relying on cellular responses? This review examines how biofunctionalization has emerged as a transformative strategy in implant surface engineering and critically analyses the latest biofunctionalization strategies for dental implants, with a particular focus on the underlying mechanisms that regulate biomolecule-implant interactions. It evaluates biomolecule incorporation via physical and covalent attachment, highlighting their distinct advantages in stability, efficiency, and scalability. We discuss approaches for functionalizing dental implant surfaces with bioactive molecules, such as proteins and peptides, and cells to replicate natural biological interactions, regulate immune responses, and enhance antimicrobial defense mechanisms. By addressing how bioengineered surfaces can be designed to actively engage with biological systems, this review provides a framework for developing next-generation implant technologies that achieve more effective and predictable PSTI, with strong potential for clinical translation.</div></div>","PeriodicalId":8762,"journal":{"name":"Bioactive Materials","volume":"53 ","pages":"Pages 540-590"},"PeriodicalIF":18.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144711543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}